London, July 18, 2025 – ViiV Healthcare, a global leader in HIV-focused pharmaceutical innovation, unveiled data from its Phase 3b VOLITION study underscoring the benefits of long-acting HIV treatment over traditional daily oral therapy. The study, presented at IAS 2025, demonstrates that approximately 89% of treatment-naïve people living with HIV successfully transitioned to a long-acting injectable regimen combining cabotegravir (Vocabria) and rilpivirine (Rekambys), marketed as Cabenuva in Canada, Australia, and the U.S.

This marks a significant step away from daily Dovato (dolutegravir/lamivudine) pills, offering patients more flexibility and improved adherence. The findings reinforce real-world data showing CAB+RPV LA’s broad effectiveness across diverse populations, including key prevention groups such as transgender individuals, Black women, and men who have sex with men, as revealed in the EBONI and PILLAR studies.

Jean van Wyk, Chief Medical Officer at ViiV Healthcare, stated, “Our VOLITION data showcases the power of choice in HIV care. Long-acting injectables like CAB+RPV LA offer not only clinical efficacy and tolerability but also align better with patients’ lifestyles, advancing our goal of ending the HIV epidemic.”

The VOLITION study further supports ViiV’s strategic focus on developing long-term solutions in HIV prevention and treatment, with three years of data demonstrating sustained viral suppression and high patient satisfaction.

For full details, visit: www.viivhealthcare.com/news/volition-study-long-acting-hiv

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com